| Secondary |
| Constipation |
10.5% |
| Infection |
10.5% |
| Convulsion Prophylaxis |
9.3% |
| Cerebral Infarction |
8.1% |
| Drug Use For Unknown Indication |
5.8% |
| Infection Prophylaxis |
4.7% |
| Wound Complication |
4.7% |
| Pyrexia |
4.4% |
| Asthma |
3.8% |
| Gastric Ulcer |
3.8% |
| Cough |
3.5% |
| Fluid Replacement |
3.5% |
| Gastritis |
3.5% |
| Hyperglycaemia |
3.5% |
| Hypertension |
3.5% |
| Neurogenic Bladder |
3.5% |
| Nutritional Support |
3.5% |
| Upper Respiratory Tract Inflammation |
3.5% |
| Vitamin Supplementation |
3.5% |
| Influenza |
3.2% |
|
| Stevens-johnson Syndrome |
31.0% |
| Cholangitis |
9.5% |
| Abnormal Behaviour |
4.8% |
| Confusional State |
4.8% |
| Dyspnoea |
4.8% |
| Haemorrhage Subcutaneous |
4.8% |
| Pneumonia |
4.8% |
| Renal Impairment |
4.8% |
| Status Asthmaticus |
4.8% |
| Toxic Skin Eruption |
4.8% |
| Atelectasis |
2.4% |
| Blood Creatine Phosphokinase Increased |
2.4% |
| Cardiac Failure |
2.4% |
| Granulocytopenia |
2.4% |
| Hyperkinesia |
2.4% |
| Pyrexia |
2.4% |
| Staphylococcal Infection |
2.4% |
| Swelling Face |
2.4% |
| Syncope |
2.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
18.7% |
| Prophylaxis |
9.3% |
| Pneumonia |
8.8% |
| Product Used For Unknown Indication |
8.6% |
| Asthma |
7.4% |
| Hypertension |
5.2% |
| Constipation |
5.1% |
| Insomnia |
4.0% |
| Nutritional Support |
3.8% |
| Bronchitis |
3.6% |
| Pneumonia Aspiration |
3.1% |
| Gastritis |
2.9% |
| Cancer Pain |
2.6% |
| Productive Cough |
2.6% |
| Sputum Retention |
2.5% |
| Wound Complication |
2.5% |
| Infection |
2.4% |
| Fluid Replacement |
2.4% |
| Cough |
2.3% |
| Rheumatoid Arthritis |
2.2% |
|
| Pneumonia |
8.7% |
| Interstitial Lung Disease |
8.0% |
| Pyrexia |
7.7% |
| White Blood Cell Count Decreased |
7.7% |
| Sepsis |
7.0% |
| Platelet Count Decreased |
6.3% |
| Renal Impairment |
6.3% |
| Death |
4.5% |
| Vomiting |
4.5% |
| Abnormal Behaviour |
4.2% |
| Osteomyelitis |
4.2% |
| Pneumonia Aspiration |
4.2% |
| Pneumocystis Jiroveci Pneumonia |
3.8% |
| Respiratory Failure |
3.8% |
| Shock |
3.8% |
| Liver Disorder |
3.5% |
| White Blood Cell Count Increased |
3.1% |
| Hallucination |
2.8% |
| Hepatic Function Abnormal |
2.8% |
| Toxic Epidermal Necrolysis |
2.8% |
|
| Interacting |
| Spinocerebellar Disorder |
100.0% |
|
| Drug Interaction |
50.0% |
| Drug Level Decreased |
50.0% |
|
